October 2021

Risk Factors for Mortality Among Patients with Gout in the Veteran's Health Administration

Lindsay Helget

University of Nebraska Medical Center

Bryant England

University of Nebraska Medical Center

Punyasha Roul

University of Nebraska Medical Center

Harlan Sayles

University of Nebraska Medical Center

Alison D. Petro

University of Nebraska Medical Center

See next page for additional authors

Tell us how you used this information in this [short survey](#).

Follow this and additional works at: <https://digitalcommons.unmc.edu/gmerj>

Part of the [Higher Education Commons](#), and the [Medicine and Health Sciences Commons](#)

Recommended Citation

Helget, L., England, B., Roul, P., Sayles, H., Petro, A. D., , Mikuls, T. R. Risk Factors for Mortality Among Patients with Gout in the Veteran's Health Administration. Graduate Medical Education Research Journal. 2021 Oct 04; 3(1).
<https://digitalcommons.unmc.edu/gmerj/vol3/iss1/14>

This Conference Proceeding is brought to you for free and open access by DigitalCommons@UNMC. It has been accepted for inclusion in Graduate Medical Education Research Journal by an authorized editor of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Risk Factors for Mortality Among Patients with Gout in the Veteran's Health Administration

Creative Commons License

This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

Lindsay Helget, Bryant England, Punyasha Roul, Harlan Sayles, Alison D. Petro, and Ted R. Mikuls

Anti-Neurofascin Antibody Associated Disease: A Case Series

Navnika Gupta¹, Afsaneh Shirani¹, Elizabeth Hartman¹, Lakshman Arcot¹, Rana Zabad¹

¹University of Nebraska Medical Center, College of Medicine, Department of Neurological Sciences

Mentor: Rana Zabad

Program: Neurological Sciences

Type: Original Research

Background: Autoantibodies against nodal and paranodal proteins, particularly anti-neurofascin (NF) antibodies, have been recently described in demyelinating disorders of the central and peripheral nervous system. There is an unmet need for further characterization of anti-NF associated demyelinating diseases. We describe the clinical and diagnostic findings of five patients with anti-NF antibodies, and attempt to identify features that might guide clinicians to check for them.

Methods: This is a retrospective chart review of five individuals seen at the University of Nebraska Medical Center Multiple Sclerosis Clinic who tested positive for serum anti-NF antibodies by western blot.

Results: In our series of five patients, the female to male ratio was 4:1, and the median age at presentation was 60 years (range: 56-70). Clinical presentations included incomplete transverse myelitis (n=2), progressive myelopathy (n=1), recurrent symmetric polyneuropathy (n=1), and non-specific neurological symptoms (n=1). Atypical features prompting further workup included co-existing upper and lower motor neuron features, older age at presentation with active disease, atypical spinal cord MRI

features and unusual CSF findings. Serum anti-NF antibody panel was positive for the NF-155 isoform in three patients (IgM n=2; IgG n=1), and the NF-140 isoform in two patients (IgG n=2).

Conclusions: Our case-series suggests that anti-NF antibodies are more commonly detected in the older populations and women. The clinical phenotype is pleiotropic. Atypical findings on MRI and paraclinical tests prompted further workup. Larger studies are needed to assess the impact of anti-NF antibodies on long-term clinical outcomes and their associated therapeutic implications. ■

<https://doi.org/10.32873/unmc.dc.gmerj.3.1.034>

Seropositive Pediatric Autoimmune Encephalitis: A Single Center Experience

Praveen Hariharan¹, Daniel A. Crespo Artunduaga¹, Geetanjali Rathore²

¹University of Nebraska Medical Center, College of Medicine, Department of Neurological Sciences

²Children's Hospital & Medical Center, Division of Pediatric Neurology

Mentor: Geetanjali Rathore

Program: Neurology

Type: Original research

Background: The objective of the study is to describe the clinical characteristics and identify unique features associated with antibody-positive autoimmune encephalitis (AE).

Methods: Charts of children aged below 18-years diagnosed with AE between 2005 and 2020 were reviewed. Demographics, clinical characteristics, laboratory, imaging, electrophysiological findings and long-term-neurological-sequelae were collected.

Results: Among 53 AE cases, 19 had serum or CSF antibodies. Among antibody-positive

AE patients, there were 9 (47%) male and 10 (53%) female patients of whom; 10 (52.6%) had anti-NMDAR-antibodies, 5 (26%) anti-VGKC-antibodies and 4 (21%) demonstrated GAD65-antibodies. Clinical presentation included neuropsychiatric symptoms (68.4%), altered mental status (63%), movement disorders (57.9%), new-onset seizures (52.6%), speech difficulties (15.7%), status epilepticus (10.5%) and sleep dysfunction (5%). Two patients (10.5%) required ICU admission and 9 (47.3%) experienced relapses needing readmissions. MRI Brain was abnormal with T2 hyperintensities in 13 patients (31.5%) - 3 in parietal lobe, 2 in temporal lobe and 2 in frontal lobe. Seven patients (36.8%) had focal EEG findings. Nine patients (47.3%) had CSF pleocytosis and protein was normal in all patients. Acute management consisted of several different combination regimens including intravenous

steroids (89%), intravenous immunoglobulin (IVIG) (84%), rituximab (15.8%) and plasma exchange (PLEX) (10.5%). Maintenance regimen included IVIG (42%), Rituximab (36.8%) and 1 PLEX. Six patients (31.5%) attained complete remission and one patient underwent excision of ovarian teratoma. Long term sequelae included neurocognitive disturbances (52.6%), epilepsy (31.5%) and movement disorders (5%).

Conclusion: The most frequent presentation of AE in our cohort was neuropsychiatric disturbances, followed by altered mental status. Given diverse clinical presentations, one should maintain broad differential diagnosis when evaluating pediatric patients with subacute onset neurological symptoms. ■

<https://doi.org/10.32873/unmc.dc.gmerj.3.1.040>

Risk Factors for Mortality Among Patients with Gout in the Veteran's Health Administration

Lindsay N. Helget^{1,2}, Bryant R. England^{1,2}, Punyasha Roul^{1,2}, Harlan Sayles^{2,3}, Alison D. Petro^{1,2}, Ted R. Mikuls^{1,2}

¹Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, NE

²University of Nebraska Medical Center, College of Medicine, Department of Internal Medicine, Division of Rheumatology

³University of Nebraska Medical Center, College of Public Health, Department of Biostatistics

Mentor: Ted Mikuls

Program: Rheumatology

Type: Original Research

Background: A complete understanding of factors driving the increased all-cause mortality risk in patients with gout is lacking. The purpose of this study was to examine

risk factors associated with mortality among patients with gout in the Veteran's Health Administration (VHA).

Methods: We performed a retrospective cohort study, identifying patients with gout using the VHA administrative data from 1/1999-9/2015 based on the presence of ≥ 2 ICD-9 codes for gout (274.X). Patients were followed from the index date until death or censoring. Potential predictors of mortality were defined using data prior to the index date. Multivariable Cox regression models were constructed to identify independent predictors of all-cause mortality.

Results: We identified 559,253 gout patients in the VHA during the study period. Over 4,250,477 patient-years of follow-up, there were 246,291 deaths. Multivariable adjusted associations with all-cause mortality are shown in Table 1. Risk factors associated with increased mortality risk included male sex, older age, Black non-Hispanic race, comorbidities, diuretic, opioid, ULT, colchicine, and steroid use. Factors associated with a lower risk of all-cause mortality included white Hispanic, black Hispanic, and Asian races, elevated BMI, comorbid HTN, and NSAID use.

Conclusion: We have preliminarily identified multiple risk factors for mortality in veterans with gout with the strongest risk factors being comorbid CVD, diabetes, lung disease, and cancer, as well as the use of steroids and opioids. Mechanisms underpinning associations between select medication use and survival will require additional study accounting for the effects of comorbid CKD is this CKD or CVD and measures of gout severity. ■

<https://doi.org/10.32873/unmc.dc.gmerj.3.1.036>

Table 1.
Patient characteristics associated with all-cause mortality in veterans with gout.

Characteristic	Adjusted HR (95% CI)*
Demographics	
Age, Years	1.06 (1.06, 1.06)
Male (vs. Female) Sex	1.07 (1.02, 1.12)
Race and Ethnicity	
White Hispanic	0.81 (0.78, 0.83)
White Non-Hispanic	Referent
Black Hispanic	0.78 (0.69, 0.89)
Black Non-Hispanic	1.06 (1.04, 1.07)
Asian	0.62 (0.59, 0.66)
Other	1.07 (1.04, 1.09)
Missing	1.95 (1.93, 1.97)
Service Connected Condition	0.84 (0.83, 0.85)
Urban Residence (vs. Rural)	1.02 (1.02, 1.03)
VHA Enrollment Duration, Years	0.95 (0.95, 0.95)
Health Factors & Comorbidities	
Body Mass Index	
<20 kg/m2	0.97 (0.93, 1.02)
20 to <25 kg/m2	Referent
25 to <30 kg/m2	0.74 (0.73, 0.75)
≥ 30 kg/m2	0.68 (0.67, 0.69)
Comorbidities	
Myocardial infarction or atherosclerosis, %	1.11 (1.09, 1.13)
Other cardiovascular disease, %	1.46 (1.45, 1.47)
Stroke, %	1.17 (1.15, 1.19)
Hypertension, %	0.90 (0.89, 0.91)
Lung disease, %	1.59 (1.57, 1.61)
Depression, %	1.15 (1.14, 1.17)
Diabetes mellitus, %	1.34 (1.32, 1.35)
Ulcer or stomach problem, %	1.06 (1.04, 1.08)
Cancer, %	1.23 (1.21, 1.24)
Diuretic Use	1.37 (1.36, 1.39)
Gout Disease Characteristics and Medication Use	
ULT Use (Allopurinol, Febuxostat, Probenecid, Pegloticase)	1.04 (1.03, 1.05)
NSAID Use	0.87 (0.86, 0.88)
Steroid Use	1.15 (1.13, 1.16)
Colchicine Use	1.08 (1.07, 1.09)
Opioid Use	1.17 (1.16, 1.19)
≥ 1 Serum Urate Test During Prior Year	0.99 (0.98, 1.00)

*All variables included in multivariable model are shown in the table
Abbreviations: VHA, Veterans Health Administration; ULT, urate lowering therapy

The Prognostic Significance of Androgen Receptor Expression in Malignant Gliomas

Ming-yang Hung¹, Nan Zhou¹, Chi Zhang¹

¹University of Nebraska Medical Center, College of Medicine, Department of Radiation Oncology

Mentor: Chi Zhang

Program: Radiation Oncology

Type: Original Research

Background: Androgen receptor (AR) overexpression has been identified in malignant gliomas, suggesting that AR plays an important role in tumor carcinogenesis. However, the prognostic significance of AR overexpression remains largely to be explored.

Methods: AR gene expression at the levels of mRNA, protein expression, and clinical data were obtained from the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. AR expression levels were compared across gliomas of different histopathologic and molecular subtypes. Lastly, Kaplan-Meier survival analyses in patients with different AR expression levels were investigated for the potential prognostic values of AR.

Results: Compared to normal brain tissue, malignant gliomas showed significantly

higher AR mRNA expression ($p < .01$). Furthermore, AR mRNA expression was more prominent in higher grade disease, regardless of histopathologic and molecular subtypes ($p < 0.01$). Similarly, at the protein level, AR protein was more abundant in GBM than in lower grade gliomas (LGG) (grade II and III) ($p < 0.0001$). This was corroborated by a linear association between AR mRNA and protein expression ($r = 0.65$, $p < 0.001$). Finally, in LGG, both high AR gene and protein expression were associated with significantly worse overall survival. Five-year overall survival for patients with LGG with high AR